^
    3d
    Fruquintinib Combined With TAS-102 Versus Bevacizumab Combined With TAS-102 for Advanced Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=292, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    7d
    - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases (clinicaltrials.gov)
    P2, N=140, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting | Initiation date: Apr 2025 --> Oct 2025
    Enrollment open • Trial initiation date • Mismatch repair • pMMR
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    9d
    The Current Role of Antiangiogenics in Colorectal Cancer. (PubMed, Int J Mol Sci)
    Among emerging therapies, the novel anti-angiogenic agent fruquintinib has recently demonstrated clinical efficacy in the treatment of mCRC. Based on the data discussed in the present narrative review, the therapeutic landscape of mCRC appears poised for significant evolution in the near future. While numerous challenges and unanswered questions remain, the emergence of innovative therapeutic combinations and agents provides a promising opportunity for improving patient outcomes in mCRC.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    Fruzaqla (fruquintinib)
    11d
    FRUQUITAS: Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma (clinicaltrials.gov)
    P3, N=324, Not yet recruiting, Federation Francophone de Cancerologie Digestive
    New P3 trial
    |
    Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    16d
    A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Fruzaqla (fruquintinib)
    16d
    Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial (clinicaltrials.gov)
    P2, N=236, Not yet recruiting, Sun Yat-sen University
    New P2 trial • Head-to-Head
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    17d
    concept: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Zhejiang University
    New P2 trial • Checkpoint inhibition • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    18d
    A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (clinicaltrials.gov)
    P3, N=703, Completed, Hutchison Medipharma Limited | Active, not recruiting --> Completed
    Trial completion
    |
    paclitaxel • Fruzaqla (fruquintinib)
    1m
    A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Kahr Bio Australia Pty Ltd
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    Tecentriq (atezolizumab) • Fruzaqla (fruquintinib) • DSP-107
    1m
    A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment (clinicaltrials.gov)
    P2, N=18, Not yet recruiting, Harbin Medical University
    New P2 trial • pMMR
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab)
    2ms
    Efficacy and Safety of QL1706 combined with Regorafenib or Fruquintinib as Third-Line Therapy for Advanced Colorectal Cancer (ChiCTR2500110556)
    P4, N=26, Not yet recruiting, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New P4 trial
    |
    Stivarga (regorafenib) • Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab)
    2ms
    Fruquintinib in combination with TAS-102 versus bevacizumab in combination with TAS-102 in the third line and later for the treatment of advanced metastatic CRC Non-randomized controlled, single-center, retrospective, cohort study (ChiCTR2500110400)
    P=N/A, N=80, Recruiting, Ningbo No.2 Hospital; Ningbo No.2 Hospital
    New trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)